Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
07/2003
07/10/2003WO2003055524A1 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
07/10/2003WO2003055523A1 Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a 4-oxobutanoic acid, and the use thereof for treating diabetes
07/10/2003WO2003055522A1 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors
07/10/2003WO2003055521A1 Remedies for mild recognition deflict
07/10/2003WO2003055516A1 Pecam-1 modulation
07/10/2003WO2003055505A2 Sk-3 potassium channels and the treatment of sexual dysfunctions and/or vascular disorders
07/10/2003WO2003055500A1 Pharmaceutical compositions for the treatment or prevention of osteoporosis
07/10/2003WO2003055498A1 Composition comprising dextrinsulfate for the treatment of sexual transmitted diseases (std)
07/10/2003WO2003055495A1 ORAL PHARMACEUTICAL PRODUCTS CONTAINING 17β-ESTRADIOL-3-LOWER ALKANOATE, METHOD OF ADMINISTERING THE SAME AND PROCESS OF PREPARATION
07/10/2003WO2003055494A1 Use of ugt inhibitors to increase bioavailability
07/10/2003WO2003055493A1 Non-nucleosidic inhibitors of reverse transcriptase as antagonists of cell proliferation and inducers of cell differentiation
07/10/2003WO2003055485A1 Dosing regimen for ppar-gamma activators
07/10/2003WO2003055482A1 Amide derivatives as gk activators
07/10/2003WO2003055481A1 Organ fibrosis inhibitors
07/10/2003WO2003055463A1 Composition comprising at least an oxazolin for inhibiting langerhans cell migration, and uses thereof
07/10/2003WO2003055456A1 Stable surfactant compositions for suspending components
07/10/2003WO2003055447A2 Heterocyclic acridone inhibitors of impdh enzyme
07/10/2003WO2003055443A2 Bone morphogenic proteins (bmp), bmp receptors and bmp binding proteins and their use in the diagnosis and treatment of glaucoma
07/10/2003WO2003055442A2 Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)
07/10/2003WO2003055440A2 Compositions and methods for the treatement of immune related diseases
07/10/2003WO2003055424A1 METHOD OF SYSTEMICALLY DELIVERING SSRIs
07/10/2003WO2003055410A2 Composition and method for treatment of otitis externa
07/10/2003WO2003043905A3 Pharmaceutical product with an adsorbent
07/10/2003WO2003039437A3 Orally administered pharmaceutical preparation comprising liposomically encapsulated paclitaxel
07/10/2003WO2003037298A3 Bowel cleansing agent
07/10/2003WO2003035670A3 Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis
07/10/2003WO2003035107A8 Enzyme inhibitors for inactivating allergens
07/10/2003WO2003020289A9 Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
07/10/2003WO2003017932A3 Compositions and methods for targeting cerebral circulation and treatment of headache
07/10/2003WO2003015872A3 Intravaginal administration of an aromatase inhibitor for the treatment of oestrogen-dependent proliferative disorders
07/10/2003WO2003011227A3 Taste masking composition
07/10/2003WO2003010140A3 Hepatitis c virus polymerase inhibitors with heterobicyclic structure
07/10/2003WO2003008452A3 Bispecific monoclonal antibodies to il-12 and il-18 receptors
07/10/2003WO2003007880A3 Inhibition of behab cleavage and primary central nervous system (cns) tumors
07/10/2003WO2003002765A3 Methods for the diagnosis of cancer based on the obcam and ntm genes
07/10/2003WO2003002175A8 Enhanced systemic absorption of intradermally delivered substances
07/10/2003WO2002101392A3 Methods for treating disorders of the nervous and reproductive systems
07/10/2003WO2002090520A3 Toll/interleukin-1 receptor adaptor protein (tirap)
07/10/2003WO2002072788A3 Chronic obstructive pulmonary disease-related immunglobulin derived proteins, compositions, methods and uses
07/10/2003WO2002063008A3 Intracellular signaling molecules
07/10/2003WO2002059326A3 Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses thereof
07/10/2003WO2002059267A3 Constitutively desensitized g protein-coupled receptors
07/10/2003WO2002040541A3 Transporters and ion channels
07/10/2003WO2002028408A9 Compositions and methods for the transport of biologically active agents across cellular barriers
07/10/2003WO2002018581A3 G-protein coupled receptors
07/10/2003WO2002009761A9 Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
07/10/2003WO2001098248A3 Hiv integrase inhibitors
07/10/2003WO2001096523A3 Polynucleotides related to colon cancer
07/10/2003US20030131370 Disruption of the glutathione S-transferase-Omega-1 gene
07/10/2003US20030131363 Controlling the activation of genetic translation, cell proliferation, especially hematopoietic cells; drug screening for compounds which alter the activity of the kinase; thalassemias, sickle cell disease, unstable hemoglobins
07/10/2003US20030130357 Inhibiting ornithine decarboxylase (involved with production of putrescine) with N(1),N(11)-diethylnorspermine
07/10/2003US20030130355 Serotonin/noradrenaline reuptake inhibitors (N-(1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutyl)-N,N-dimethylamine; dietetics; side effects reduction
07/10/2003US20030130350 Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis
07/10/2003US20030130335 Protein tyrosine phosphatases inhibitors
07/10/2003US20030130334 Methods and compositions for the treatment of psychiatric disorders
07/10/2003US20030130333 Combination product and methods of use
07/10/2003US20030130330 Materials and methods for the treatment of hypertension and angina
07/10/2003US20030130324 Method for preventing or controlling cataract
07/10/2003US20030130322 Biaryl ether derivative as opiod antagonist
07/10/2003US20030130316 Method for chemoprevention of prostate cancer
07/10/2003US20030130306 Abntidiabetic agents, cardiovascular disorders, anticholesterol agents
07/10/2003US20030130305 Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease
07/10/2003US20030130303 Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
07/10/2003US20030130299 Administering dosage of immunology response moderator
07/10/2003US20030130294 Pyrimidine 3-oxide compounds for inducing/stimulating hair growth and/or retarding hair loss
07/10/2003US20030130292 Immunosuppressants; autoimmune disease; skin disorders; Crohn's disease; antidiabetic agents; anticancer agents; antiarthritic agents
07/10/2003US20030130273 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
07/10/2003US20030130266 Pharmacological treatment for sleep apnea
07/10/2003US20030130264 Methods of using pyrimidine-based antiviral agents
07/10/2003US20030130263 Mixture of two antihistamines; sustained release
07/10/2003US20030130250 Methods to mobilize progenitor/stem cells
07/10/2003US20030130244 Mixture of estrogen, androgen and anticholinergic agent
07/10/2003US20030130242 Administering hypocalcemic hydroxyvitamin d compound having ahydrocarbon moiety at the c-24 position as anticarcinogenic agent
07/10/2003US20030130236 Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs
07/10/2003US20030130225 Urogenital disorders; concurrent administering fluconazole by mouth and topical applying fungicide in situ
07/10/2003US20030130216 Use of inhibitors of caspase-3 or caspase-activated desoxyribonuclease(cad) for treating cardiac disease
07/10/2003US20030130210 Method for treating a patient with neoplasia by treatment with an anthracycline antibiotic
07/10/2003US20030130201 Mixture with ascorbic acid, proline and lysine
07/10/2003US20030130200 Tripeptide or tetrapeptide
07/10/2003US20030130182 Secreted and transmembrane polypeptides and nucleic acids encoding the same
07/10/2003US20030130180 Utilization of an aminopeptidase inhibitor
07/10/2003US20030130171 Inhibitors of ABC drug transporters in multidrug resistant microbial cells
07/10/2003US20030130169 Methods of treating drug-resistant bacterial infections
07/10/2003US20030130165 Method for treating neurodegenerative disorders
07/10/2003US20030129706 Fhm, a novel member of the TNF ligand supergene family
07/10/2003US20030129702 DNA encoding galanin GALR2 receptors and uses thereof
07/10/2003US20030129696 Polynucleotides and polypeptides encoding receptors
07/10/2003US20030129686 Novel nucleic acid and polypeptide molecules
07/10/2003US20030129678 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer
07/10/2003US20030129663 Methods and compositions for modulating oxidized ldl transport
07/10/2003US20030129662 Use of vascular endothelial growth factor (VEGF)
07/10/2003US20030129645 Can be used as models for the development of human therapeutic targets, aid in the identification of therapeutic proteins, and serve as targets for the development of human therapeutic agents that modulate kinase activity
07/10/2003US20030129644 Used in gene therapy
07/10/2003US20030129606 Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
07/10/2003US20030129596 Chemical compounds
07/10/2003US20030129278 Oligosaccharide mixture
07/10/2003US20030129266 Interleukin-4 production inhibitors
07/10/2003US20030129265 Interleukin-4 production inhibitors
07/10/2003US20030129261 Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
07/10/2003US20030129241 Effective amount of a vasoactive prostaglandin, a polysaccharide thickener, a lipophilic component, and an acidic buffer system
1 ... 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 ... 1151